- Previous Close
6.97 - Open
7.05 - Bid 6.00 x --
- Ask 6.62 x --
- Day's Range
6.63 - 7.18 - 52 Week Range
6.63 - 11.90 - Volume
14,690 - Avg. Volume
4,649 - Market Cap (intraday)
130.776M - Beta (5Y Monthly) 0.54
- PE Ratio (TTM)
-- - EPS (TTM)
-1.03 - Earnings Date Apr 1, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.
www.newron.comRecent News: NP5.DE
View MorePerformance Overview: NP5.DE
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NP5.DE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NP5.DE
View MoreValuation Measures
Market Cap
124.63M
Enterprise Value
161.30M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
17.76
Price/Book (mrq)
--
Enterprise Value/Revenue
23.14
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-270.17%
Return on Assets (ttm)
-33.24%
Return on Equity (ttm)
--
Revenue (ttm)
6.97M
Net Income Avi to Common (ttm)
-18.83M
Diluted EPS (ttm)
-1.03
Balance Sheet and Cash Flow
Total Cash (mrq)
12.19M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-11.36M